TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06810544: Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 191 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$3,141,600

Rescue Site Savings

+$2,081,310

Unlock Full NCT06810544 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06810544 Rescue Dossier →